Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer - PubMed
4 hours ago
- #immunotherapy
- #clinical trial
- #colon cancer
- Atezolizumab plus mFOLFOX6 improves disease-free survival in stage III dMMR colon cancer patients.
- Phase 3 trial with 712 patients (355 in atezolizumab-mFOLFOX6 group, 357 in mFOLFOX6 alone group).
- 3-year disease-free survival was 86.3% (atezolizumab-mFOLFOX6) vs. 76.2% (mFOLFOX6 alone).
- Hazard ratio for disease recurrence or death was 0.50 (95% CI, 0.35 to 0.73; P<0.001).
- Higher grade 3 or 4 adverse events in atezolizumab-mFOLFOX6 group (84.1%) vs. mFOLFOX6 alone (71.9%).